益盛药业(002566) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥148,369,275.22, a decrease of 5.93% compared to the same period last year[4] - Net profit attributable to shareholders increased by 112.12% to ¥5,364,562.46, while net profit excluding non-recurring gains and losses decreased by 37.81% to ¥12,561,156.24[4] - Basic and diluted earnings per share were both ¥0.0162, reflecting an increase of 113.16% year-on-year[4] - Total operating revenue decreased to ¥476,195,233.12 from ¥505,560,683.83, representing a decline of approximately 5.7% year-over-year[20] - Net profit for the period was ¥24,418,791.01, down from ¥33,402,435.53, reflecting a decrease of approximately 26.9% year-over-year[22] - Earnings per share (EPS) decreased to ¥0.0729 from ¥0.1084, a decline of about 32.7% year-over-year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,983,619,110.84, a 0.44% increase from the previous year[5] - The company's total assets as of September 30, 2025, amounted to CNY 2,983,619,110.84, an increase from CNY 2,970,654,385.62 at the beginning of the period[16] - Current assets increased to CNY 2,414,642,306.45 from CNY 2,375,780,311.63, reflecting a growth of approximately 1.12%[17] - Total liabilities increased to ¥658,861,084.23 from ¥637,219,990.02, reflecting an increase of approximately 3.9% year-over-year[18] - The company's total liabilities increased, with current liabilities including accounts payable decreasing to CNY 10,663,685.39 from CNY 13,001,831.67, a decline of approximately 18%[17] Cash Flow - Cash flow from operating activities for the year-to-date was ¥41,548,844.03, showing a slight increase of 0.91%[4] - Cash inflow from operating activities totaled ¥535,723,149.74, down from ¥600,832,070.69, indicating a decrease of approximately 10.8% year-over-year[23] - The net cash flow from operating activities was $41,548,844.03, showing a slight increase from $41,175,388.85 in the previous period[24] - The total cash outflow from operating activities was $494,174,305.71, down from $559,656,681.84 in the prior period[24] Investment and Financial Activities - The company reported a significant increase in investment income, which rose by 141.28% to ¥11,565,434.04 due to gains from the disposal of financial assets[8] - Financial expenses increased to ¥9,608,017.34 from ¥4,351,479.19, representing an increase of approximately 120.5% year-over-year[21] - Cash inflow from investment activities totaled $461,881,788.97, significantly up from $105,257,875.37 in the prior period[24] - The company received $450,000,000.00 from investment recoveries, a significant increase from $100,000,000.00 previously[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,569, with the largest shareholder holding 39.08% of the shares[10] - The company is addressing issues related to shareholding transparency and has implemented a plan to reduce the number of shares held in trust[13] - The company reported that certain shareholders have resolved their shareholding issues, ensuring compliance with regulatory requirements[14] - The company is committed to protecting the interests of minority investors during the share reduction process[14] Expenses - Total operating costs decreased to ¥461,908,412.48 from ¥487,965,647.77, a reduction of about 5.3% year-over-year[20] - Research and development expenses were ¥11,554,503.24, down from ¥14,377,485.51, a decrease of about 19.5% year-over-year[21] - The company paid $87,882,445.89 to employees, a decrease from $110,162,283.72 in the previous period[24] - The company’s cash outflow for taxes was $68,038,842.62, down from $75,704,346.51 in the prior period[24]